RARα agonists(Retinoic acid receptor alpha agonists), RARβ2 agonists(Retinoic acid receptor beta agonists), RARγ agonists(Retinoic acid receptor gamma agonists)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesOther Diseases+ [1]

Active Indication

Facial wrinklesHyperpigmentationAcne Vulgaris+ [2]

Inactive Indication

Chronic liver disease

Originator Organization

Allergan Ltd. (Ireland)

Active Organization

Allergan, Inc.

Chongqing Huapont Pharmaceutical Co. Ltd.

Mayne Pharma Ltd.

+ [3]

Inactive Organization

Bausch Health Americas, Inc.

Drug Highest PhaseApproved

First Approval Date

US (13 Jun 1997),

Acne VulgarisPlaque psoriasis

Regulation-

Structure

Molecular FormulaC21H21NO2S

InChIKeyOGQICQVSFDPSEI-UHFFFAOYSA-N

CAS Registry118292-40-3

Clinical Trials associated with Tazarotene

NCT06331624 / RecruitingPhase 2

Biomarker Modulation and the Inhibition of Natural Killer Type 1 (NKT1) Cells by Oral GRI-0621 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An interim analysis will be performed when 24 subjects complete 6 weeks of treatment (approximately 8 placebo subjects).

Start Date01 Mar 2024

Sponsor / Collaborator

GRI Bio Operations, Inc.

CTRI/2023/11/060308 / Not yet recruitingNot Applicable

Comparative efficacy of different concentration of topical tazarotene and topical tretinoin in acne vulgaris. - NIL

Start Date05 Dec 2023

Sponsor / Collaborator-

CTRI/2023/10/059038 / RecruitingNot ApplicableIIT

Comparative efficacy of topical methotrexate and topical tazarotene in psoriasis vulgaris - NIL

Start Date31 Oct 2023

Sponsor / Collaborator

Government Medical College

100 Clinical Results associated with Tazarotene

100 Translational Medicine associated with Tazarotene

100 Patents (Medical) associated with Tazarotene

544

Literatures (Medical) associated with Tazarotene

01 Feb 2024·Journal of drugs in dermatology : JDD

Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion With a Ceramide-Containing Moisturizer in Adults With Psoriasis

Article

Author: Jacobson, Abby ; Kircik, Leon

INTRODUCTION:

Moisturizers are often used as adjuvant therapy for psoriasis to assist with rehydration and skin barrier restoration. Fixed-combination halobetasol propionate 0.01% and tazarotene 0.045% lotion (HP/TAZ) is indicated for the topical treatment of plaque psoriasis in adults, with a demonstrated clinical profile in two phase 3 trials. However, the effect of application order with HP/TAZ has yet to be explored. This study evaluated the clinical profile of HP/TAZ applied before versus after a ceramide-containing moisturizer in adults with mild-to-moderate plaque psoriasis.

METHODS:

Sixteen participants were randomized to apply HP/TAZ followed by moisturizer on one side and moisturizer followed by HP/TAZ on the other side once daily for 12 weeks. Tolerability, safety, efficacy, and quality of life endpoints were assessed. Results: Significant Investigator's Global Assessment improvement was observed across all time points (P≤0.003) regardless of application order. Total Dermatology Life Quality Index scores significantly improved at all time points (P≤0.003), and visual analog scale for itch significantly improved at weeks 4, 8, and 12 (P<0.008). Four moderate adverse events were experienced by 3 participants. Two participants reported itching/irritation, which was worse when HP/TAZ was applied first.

CONCLUSIONS:

The application order of moisturizer did not decrease therapeutic efficacy of HP/TAZ. Moisturizer application before HP/TAZ may reduce incidence of application site adverse events, ultimately increasing tolerability and supporting the real-world recommendation that applying a ceramide-containing moisturizer before HP/TAZ, versus after, results in a safe and effective therapeutic option for plaque psoriasis. J Drugs Dermatol. 2024;23(2):50-53. doi:10.36849/JDD.7928.

01 May 2024·Journal of cosmetic dermatology

Efficacy of ceramides and niacinamide‐containing moisturizer versus hydrophilic cream in combination with topical anti‐acne treatment in mild to moderate acne vulgaris: A split face, double‐blinded, randomized controlled trial

Article

Author: Tempark, Therdpong ; Shem, Andrew ; Lueangarun, Suparuj

Abstract:

Introduction:

Topical therapy is the mainstay treatment of acne, and topical retinoids such as tretinoin, tazarotene, and adapalene are recommended as the first‐line therapy for mild to moderate acne. However, the cutaneous irritations may occur, and the dermocosmetics are recommended to prevent side effects of anti‐acne drugs and adhere to treatment. Thus, this study aims to compare the efficacy and tolerability of ceramides and niacinamide‐containing moisturizer (CCM) versus hydrophilic cream in combination with topical anti‐acne treatment in mild to moderate acne vulgaris.

Methods:

This was an 8‐week, randomized, double‐blinded, split face study in 40 patients assigned for topical anti‐acne medications (5% benzoyl peroxide and 0.1% adapalene gel), then randomly applied CCM or hydrophilic cream. All patients were followed at week 0, 2, 4, and 8 for acne improvement, adverse reactions, biometric, and biophysical evaluation.

Results:

CCM could significantly improve the non‐inflammatory, inflammatory, and total acne lesions compared with hydrophilic cream after week 8 of treatment. Interestingly, there was an improvement of global worst score, hemoglobin index, melanin index, TEWL, skin hydration, sebum production, and skin surface pH, with no statistically significant differences between the two treatments. No serious side effects from clinical application of CCM and hydrophilic cream in mild to moderate acne vulgaris patients.

Conclusion:

Ceramide and niacinamide‐containing moisturizer in combination with anti‐acne medication can significantly improve acne lesions and decrease cutaneous irritations toward a satisfactory treatment outcome of mild to moderate acne vulgaris.

31 Dec 2023·The Journal of dermatological treatment

Efficacy and safety of topical treatments for seborrheic keratoses: a systematic review

Review

Author: Grichnik, James ; Natarelli, Nicole ; Moore, Sarah ; Hennessy, Kerry ; Krenitsky, Amanda

Seborrheic keratoses (SKs) are benign epidermal neoplasms presenting as waxy, brown to black papules and plaques. Patients often seek removal for cosmetic reasons or irritation. The objective of this systematic review is to assess the efficacy and safety of topical treatments for SKs. Studies involving any topical medication indicated for SK removal were retrieved from Embase, Scopus, PubMed, and Cochrane. The final search was conducted on November 9, 2021, and 26 reports met inclusion criteria. A quality rating scheme was utilized to assess evidence quality. Heterogeneity of treatments and outcome measures precluded meta-analysis. Topical treatments that yielded a good-to-excellent response include hydrogen peroxide, Maxacalcitol 25 µg/g, BID Tazarotene 0.1% cream, 5% potassium dobesilate cream, 1% diclofenac sodium solution, urea-based solution, and 65% and 80% trichloroacetic acid. Local skin reactions were often mild and transient. Topical hydrogen peroxide showed the greatest evidence for clinical clearance of SKs, although there are no studies to our knowledge that directly compared hydrogen peroxide to current first-line treatments (e.g. cryotherapy or shave excision). The results of this review suggest viable and safe treatment of SK with topical therapies; however, there remains demand for topical treatments that reliably equate or exceed the efficacy of current first-line therapies.Key PointsQuestion: Are safe and efficacious topical treatments for seborrheic keratoses available?Findings: Topical treatments for seborrheic keratoses yield different responses and may be associated with local skin reactions. Topical hydrogen peroxide shows the greatest evidence for clinical clearance of seborrheic keratoses and may be a viable option for patients requesting noninvasive removal. No studies to our knowledge directly compare hydrogen peroxide to current first-line treatments.Meaning: There remains demand for topical treatments that reliably equate or exceed the efficacy of current first-line therapies.

News (Medical) associated with Tazarotene

14 Jun 2024

·www.globenewswire.com

GRI Bio Announces Reverse Stock Split

GRI’s common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-13 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on June 7, 2024. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on June 17, 2024. The Company’s common stock will open for trading under a new CUSIP number 3622AW 304 on The Nasdaq Capital Market on June 18, 2024, on a split-adjusted basis under the current ticker symbol “GRI.” The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The 1-for-13 Reverse Split will automatically convert every thirteen (13) current shares of the Company’s common stock into one (1) share of common stock. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fractional share of the Company’s common stock following the reverse stock split will receive a cash payment in lieu thereof at a price equal to that fractional share to which the stockholder would otherwise be entitled multiplied by the closing sale price of the common stock on The Nasdaq Capital Market, as adjusted for the reverse stock split, on June 17, 2024. The reverse split will reduce the number of shares of outstanding common stock from approximately 6,605,271 shares, the number of shares outstanding as of June 13, 2024, to approximately 508,091 shares. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise and conversion prices of the Company’s outstanding stock options, warrants, and convertible securities, and to the number of shares issued and issuable under the Company’s stock incentive plans. Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers’ particular processes, and will not be required to take any action in connection with the reverse stock split. For those stockholders holding physical stock certificates, the Company’s transfer agent, Broadridge Corporate Issuers Solutions, Inc., will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable. About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline. Forward Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the timing and effectiveness of the Reverse Split; the Company’s ability to regain compliance with the Nasdaq minimum bid price and other listing requirements; the Company’s expectations with respect to development and commercialization of the Company’s product candidates; the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company’s common stock on Nasdaq and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company’s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company’s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) the failure to achieve any milestones or receive any milestone payments under any agreements; (10) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (12) other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 28, 2024 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Investor Contact:JTC Team, LLCJenene Thomas(833) 475-8247GRI@jtcir.com

Cell Therapy

14 Jun 2024

·www.biospace.com

GRI Bio Announces Reverse Stock Split - June 14, 2024

GRI’s common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-13 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on June 7, 2024. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on June 17, 2024. The Company’s common stock will open for trading under a new CUSIP number 3622AW 304 on The Nasdaq Capital Market on June 18, 2024, on a split-adjusted basis under the current ticker symbol “GRI.” The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The 1-for-13 Reverse Split will automatically convert every thirteen (13) current shares of the Company’s common stock into one (1) share of common stock. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fractional share of the Company’s common stock following the reverse stock split will receive a cash payment in lieu thereof at a price equal to that fractional share to which the stockholder would otherwise be entitled multiplied by the closing sale price of the common stock on The Nasdaq Capital Market, as adjusted for the reverse stock split, on June 17, 2024. The reverse split will reduce the number of shares of outstanding common stock from approximately 6,605,271 shares, the number of shares outstanding as of June 13, 2024, to approximately 508,091 shares. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise and conversion prices of the Company’s outstanding stock options, warrants, and convertible securities, and to the number of shares issued and issuable under the Company’s stock incentive plans. Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers’ particular processes, and will not be required to take any action in connection with the reverse stock split. For those stockholders holding physical stock certificates, the Company’s transfer agent, Broadridge Corporate Issuers Solutions, Inc., will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable. About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline. Forward Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the timing and effectiveness of the Reverse Split; the Company’s ability to regain compliance with the Nasdaq minimum bid price and other listing requirements; the Company’s expectations with respect to development and commercialization of the Company’s product candidates; the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company’s common stock on Nasdaq and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company’s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company’s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) the failure to achieve any milestones or receive any milestone payments under any agreements; (10) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (12) other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 28, 2024 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 GRI@jtcir.com

Cell Therapy

11 Jun 2024

·www.globenewswire.com

GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference

Live video webcast on Tuesday, June 18th at 11:00 AM ET LA JOLLA, CA, June 11, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 11:00 AM ET. As part of the event, Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will provide an “elevator pitch” and outline the Company’s upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed. A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (gribio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days. About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline. Investor Contact:JTC Team, LLCJenene Thomas(833) 475-8247GRI@jtcir.com

Cell TherapyImmunotherapy

100 Deals associated with Tazarotene

External Link

KEGG	Wiki	ATC	Drug Bank
D01132	Tazarotene	D05AX05	DB00799

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Facial wrinkles	US	Allergan, Inc.	30 Sep 2002
Hyperpigmentation	US	Allergan, Inc.	30 Sep 2002
Acne Vulgaris	US	Allergan, Inc.	13 Jun 1997
Plaque psoriasis	US	Allergan, Inc.	13 Jun 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic liver disease	Phase 2	ZA	GRI Bio Operations, Inc.	01 Sep 2015
Idiopathic Pulmonary Fibrosis	IND Approval	GB	GRI Bio Operations, Inc.	04 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04071756 (CTgov)	Phase 2	Solid tumor \| Hand-Foot Syndrome	8	Topical Tazarotene (Topical Tazarotene 0.1% Gel Plus BPS)	knczhnchik(excudsamov) = lhsashtaek ekfuuhwpng (zdpggitxbc, xtxnxchjlt - upovfwlgnw) View more	-	15 Nov 2023
				Placebo (Placebo Gel Plus BPS)	knczhnchik(excudsamov) = kdfnllrgfm ekfuuhwpng (zdpggitxbc, yoonieoarb - gcmbxesdja) View more
WCD2023	Not Applicable	Onychomycosis	20	Topical 0.1% tazarotene gel	xkzoadknub(tjwkqilslj) = qppdlhpewr tulsscbxbj (imuxodpfgd )	Positive	07 Jul 2023
AAD2023	Not Applicable	Photodamaged skin	18	Tazarotene 0.045% Lotion	uaqofjkecy(oslhjfdmov) = rnsrznrfhx urupzhiyng (lszbniqvmv )	-	17 Mar 2023
NCT02462083 (Pubmed \| J Eur Acad Dermatol Venereol) Manual	Phase 3	Plaque psoriasis	550	HP 0.01%/TAZ 0.045% lotion	ejvqnkblsy(qwcdxtlhab) = yjvldrkwyd yzmortrmcw (coejmwzszy ) View more	Positive	01 May 2021
NCT03599193 (CTgov)	Phase 2	Acne Vulgaris	58	Tazarotene Lotion, 0.1% (DFD-03 Lotion)	flmrhjzmxi(awyrscxjsn) = tcrogeshdg cfauaabwje (fjeeofkbba, szdefmekxn - xfcwbwjzkf) View more	-	14 Sep 2020
				Tazarotene Cream, 0.1% (Tazorac Cream)	flmrhjzmxi(awyrscxjsn) = hbzbsbeuwg cfauaabwje (fjeeofkbba, wslzayoemw - bbzsdcbcez) View more
NCT03292640 (CTgov)	Phase 3	Acne Vulgaris	547	DFD-03 (0.1% tazarotene) Lotion (DFD-03 Lotion (0.1% Tazarotene))	tjbxjbknad(xdhuriwouj) = jelndqxndc ncwvpukalv (geikovuseb, rencdzlvsz - egprmliimz) View more	-	09 Jun 2020
				DFD-03 (0% tazarotene) Lotion (Placebo) (DFD-03 Vehicle (0% Tazarotene))	tjbxjbknad(xdhuriwouj) = qklnxwptjg ncwvpukalv (geikovuseb, eawhlomvlk - fyjnfxvfbn) View more
NCT03290027 (DFD-03, CTgov)	Phase 3	Acne Vulgaris	550	DFD-03 (Active)	ipgphsjyuo(lfaxxhqkbh) = hsccbenskt pjuseqvqux (ewlahjaium, vwxtwqcjsm - exeoxysuvi) View more	-	26 May 2020
				Placebo Comparator (Vehicle)	ipgphsjyuo(lfaxxhqkbh) = lfhizddklj pjuseqvqux (ewlahjaium, cgxbbdprhe - ftqielmfhm) View more
NCT02886702 (CTgov)	Phase 3	Plaque psoriasis	855	Tazarotene Cream 0.05% (Test)	hvzrzqkens(ernkzhtklt) = onauihccbj grjvraygkz (vtahukibpm, sgaspmvlac - ketqzoqdoo) View more	-	29 Aug 2018
				TAZORAC® (tazarotene) Cream 0.05% (Reference)	hvzrzqkens(ernkzhtklt) = qbpwqvakrc grjvraygkz (vtahukibpm, eshmhhzfbo - nbcusaxdwv) View more
NCT02886715 (CTgov)	Phase 3	Acne Vulgaris	1,110	Tazarotene Cream 0.1% (Test)	csdvevjhbv(ozqogougrt) = mqvqddbdhx mgzcmrdoip (ixxqudxspm, wrzeocdkxi - jcwglthxnk) View more	-	17 Aug 2018
				Tazorac® (Reference)	csdvevjhbv(ozqogougrt) = pdzagriwfo mgzcmrdoip (ixxqudxspm, scivfjsser - whyqpdhqfk) View more
NCT00713609 (CTgov)	Phase 2	Acne Vulgaris	591	Clindamycin+Benzoyl Peroxide+Tazarotene (Benzoyl Peroxide/Clindamycin + Tazarotene)	gylmarokdy(swonvyocpl): P-Value = 0.692; P-Value = <0.001; P-Value = 0.006 View more	-	06 Mar 2017
				Clindamycin+Benzoyl Peroxide (Benzoyl Peroxide/Clindamycin + Vehicle Cream)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis